Arcus Biosciences (RCUS) EBT: 2017-2025
Historic EBT for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -$135.0 million.
- Arcus Biosciences' EBT fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$432.0 million, marking a year-over-year decrease of 60.59%. This contributed to the annual value of -$282.0 million for FY2024, which is 6.31% up from last year.
- As of Q3 2025, Arcus Biosciences' EBT stood at -$135.0 million, which was down 20.54% from -$112.0 million recorded in Q1 2025.
- In the past 5 years, Arcus Biosciences' EBT registered a high of $281.5 million during Q4 2021, and its lowest value of -$135.0 million during Q3 2025.
- Moreover, its 3-year median value for EBT was -$86.0 million (2023), whereas its average is -$83.0 million.
- Data for Arcus Biosciences' EBT shows a peak YoY increase of 641.47% (in 2021) and a maximum YoY decrease of 4,379.64% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Arcus Biosciences' EBT stood at $281.5 million in 2021, then crashed by 123.80% to -$67.0 million in 2022, then decreased by 19.40% to -$80.0 million in 2023, then dropped by 16.25% to -$93.0 million in 2024, then slumped by 46.74% to -$135.0 million in 2025.
- Its last three reported values are -$135.0 million in Q3 2025, -$112.0 million for Q1 2025, and -$93.0 million during Q4 2024.